[go: up one dir, main page]

NO20072155L - Clostridium-nevrotoksiner for anvendelse i vevheling - Google Patents

Clostridium-nevrotoksiner for anvendelse i vevheling

Info

Publication number
NO20072155L
NO20072155L NO20072155A NO20072155A NO20072155L NO 20072155 L NO20072155 L NO 20072155L NO 20072155 A NO20072155 A NO 20072155A NO 20072155 A NO20072155 A NO 20072155A NO 20072155 L NO20072155 L NO 20072155L
Authority
NO
Norway
Prior art keywords
neurotoxins
tissue
clostridium
local administration
clostridium neurotoxins
Prior art date
Application number
NO20072155A
Other languages
English (en)
Inventor
Harold Victor Taylor
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of NO20072155L publication Critical patent/NO20072155L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Naturlig forekommende og/eller modifiserte Clostridium-nevrotoksiner, innbefattet slike nevrotoksiner frie for kompleksbindende proteiner som naturlig danner komplekser med Clostridium-nevrotoksiner, anvendes for å fremme heling av skadd overflatevev eller overflatisk vev hos en pasient ved lokal tilførsel i eller i nærheten av det skadde vev. Slike nevrotoksiner kan med fordel benyttes i sårheling og for å forhindre arrdannelse og kan anvendes innen området oftalmologi, f.eks. i behandling av skadd hornhinnevev, f.eks. ved lukking av betente øyne. En videre utførelse omfatter diagnostisk anvendelse for evaluering av effektiv toksintilførsel og medikamenter for anvendelse til dette.
NO20072155A 2004-09-27 2007-04-26 Clostridium-nevrotoksiner for anvendelse i vevheling NO20072155L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61339204P 2004-09-27 2004-09-27
PCT/GB2005/003728 WO2006035225A1 (en) 2004-09-27 2005-09-27 Clostridial neurotoxins for use in tissue healing

Publications (1)

Publication Number Publication Date
NO20072155L true NO20072155L (no) 2007-04-26

Family

ID=35355850

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072155A NO20072155L (no) 2004-09-27 2007-04-26 Clostridium-nevrotoksiner for anvendelse i vevheling

Country Status (13)

Country Link
US (1) US20060067950A1 (no)
EP (1) EP1799254A1 (no)
KR (1) KR20070057862A (no)
CN (1) CN101027083A (no)
AU (1) AU2005288758A1 (no)
BR (1) BRPI0516134A (no)
CA (1) CA2580122A1 (no)
EA (1) EA200700739A1 (no)
IL (1) IL182153A0 (no)
MX (1) MX2007003407A (no)
NO (1) NO20072155L (no)
WO (1) WO2006035225A1 (no)
ZA (1) ZA200702484B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
AR061669A1 (es) 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
WO2015126527A1 (en) * 2014-02-18 2015-08-27 Kaufman-Janette Joely Botulinum neurotoxin for use in the prophylactic treatment of cutaneous wounds
US20200023044A1 (en) * 2017-03-22 2020-01-23 Bonti, Inc. Botulinum neurotoxins for treating traumatic injuries
EP3600221A4 (en) * 2017-03-22 2021-01-13 Bonti, Inc. BOTULINARY NEUROTOXINS FOR USE IN THERAPY
CN107469065B (zh) * 2017-07-19 2021-05-18 广州医科大学 类蛇毒三胜肽在制备用于治疗皮肤溃疡的药物中的应用
US20190183987A1 (en) * 2017-12-18 2019-06-20 Bonti, Inc. Neurotoxins for use in minimizing scarring

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE216589T1 (de) * 1996-11-27 2002-05-15 William J Binder Neurotoxine zur behandlung von hauterkrankungen bei säugetieren
KR20010089347A (ko) * 1998-10-27 2001-10-06 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 상처 치료 증진 방법
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders

Also Published As

Publication number Publication date
MX2007003407A (es) 2007-05-23
CA2580122A1 (en) 2006-04-06
EA200700739A1 (ru) 2007-10-26
IL182153A0 (en) 2007-07-24
US20060067950A1 (en) 2006-03-30
CN101027083A (zh) 2007-08-29
BRPI0516134A (pt) 2008-08-26
WO2006035225A1 (en) 2006-04-06
KR20070057862A (ko) 2007-06-07
AU2005288758A1 (en) 2006-04-06
ZA200702484B (en) 2008-11-26
EP1799254A1 (en) 2007-06-27

Similar Documents

Publication Publication Date Title
NO20072155L (no) Clostridium-nevrotoksiner for anvendelse i vevheling
ECSP077328A (es) Neurotoxinas clostridiales para uso en la cicatrización de tejidos
Elsaie Update on management of keloid and hypertrophic scars: a systemic review
BR112016003358A2 (pt) método para aumentar a expressão de proteínas codificadas por rna
Verma et al. Office-based injection laryngoplasty for the management of unilateral vocal fold paralysis
Parikh et al. Strategies to minimize surgical scarring: translation of lessons learned from bedside to bench and back
Bharadia et al. Hypertrophic scar
WO2009142772A3 (en) Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
CO6640331A2 (es) Tratamiento anti-envejecimiento de la piel
Hong et al. Impending skin necrosis after dermal filler injection: a “golden time” for first‐aid intervention
BRPI0922789A2 (pt) peptídeo de ligação de albumina intermediador para reconhecimento de doença
MX2021009696A (es) Vectores de genoterapia para el tratamiento de la enfermedad de danon.
MY190257A (en) Optimised subcutaneous therapeutic agents
Arenbergerova et al. Effect of topical haemoglobin on venous leg ulcer healing.
MX2011010781A (es) Una crema medicinal hecha con sulfadiazina de plata y quitosano y un proceso para hacerla.
CY1117854T1 (el) Πεπτιδικη φαρμακοτεχνικη μορφη για τοπικη οφθαλμικη χρηση
Cha et al. Does fibrin sealant reduce seroma after immediate breast reconstruction utilizing a latissimus dorsi myocutaneous flap?
JP2020511548A5 (no)
MX2022010186A (es) Neurotoxinas botulinas para uso en terapia.
ES2525009T3 (es) Glucoproteínas que tienen propiedades de movilización de lípidos y usos terapéuticos de las mismas
CY1109733T1 (el) Χρησιμοποιηση πολυαιθυλενο γλυκολης για τη θεραπεια παθησεων ασθενειων και τραυματων, που εχουν σχεση με φλεγμονη
BRPI0800085A2 (pt) composição farmacêutica e curativo para tratamento de lesões de pele, bem como uso de sal de cério associado a uma matriz de colágeno
TR201908487T4 (tr) Oftalmolojik bileşimler ve kullanımları.
ES2421407T3 (es) Agente y composición para la curación de heridas
EP4588487A3 (en) Treatment of warts

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application